Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | S100B | P04271 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109396 | 0.83 | NOS2 (0.48) | NOS3NOS2POLBCD44KDM4E | |
| SCHEMBL7060663 | 0.82 | NOS3 (0.37) | NOS3NOS2POLBCD44KDM4E | |
| SCHEMBL982159 | 0.81 | NOS2 (0.47) | NOS3NOS2POLBCD44KDM4E | |
| SCHEMBL2954428 | 0.81 | NOS2 (0.42) | NOS3NOS2POLBCD44KDM4E | |
| SCHEMBL9819071 | 0.80 | SKP2 (0.53) | NOS2POLBCD44KDM4ES100B | |
| SCHEMBL5697401 | 0.79 | NOS3 (0.41) | NOS3NOS2POLBCD44KDM4E | |
| Hydrochloric Acid SCHEMBL7256311 | 0.79 | NOS2 (0.45) | NOS3NOS2POLBCD44KDM4E | |
| SCHEMBL215981 | 0.79 | NOS3 (0.41) | NOS3NOS2POLBKDM4ES100B | |
| SCHEMBL27819320 | 0.79 | SKP2 (0.47) | NOS2POLBCD44KDM4EESR1 | |
| SCHEMBL23372155 | 0.77 | NOS3 (0.39) | NOS3NOS2POLBKDM4ES100B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113201804-B | Fiber and preparation method thereof | 上海邃铸科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-113201804-A | Fiber and preparation method thereof | 上海邃铸科技有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-110476243-A | The manufacturing method of electronic circuit protection materials, electronic circuit protection materials sealing material, encapsulating method and semiconductor device | HITACHI CHEMICAL CO LTD | 2019-11-19 | — | — | CN | disclosed |
| US-6936607-B2 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNOBECK A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| EP-0421393-A2 | Resin, compositions, shaped articles, and methods for manufacture | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | NOS3 3321/4885NOS2 4235/4885POLB 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.